CTOs on the Move

Millenium Laboratories

www.millenniumlabs.com

 
Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, is transforming the way health care providers improve clinical outcomes. Millennium helps practitioners provide personalized care to patients in need through its patient-centered research and education initiatives and its ability to respond to evolving health care challenges with advanced technologies.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

California Imaging Svc

California Imaging Svc is a Fairfield, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

It for Health

It for Health is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Test Equipment Distributors

Test Equipment Distributors is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LunchboxWax

Welcome to LunchboxWax, a place that proves that chic and cheeky do, in fact, co-exist. Our refined, unique speed-waxing technique means smooth skin is just minutes away. You won`t be at LunchboxWax long, but while you`re here, you`ll feel like you`re the only one who matters. Because to us, you are. Great things happen when you choose to do one thing and do it well. That`s why we believe our Lunchbox waxologists are the best. They`re committed to their craft and your happiness. It`s all they do. Just like we handpick our waxologists, we assemble other experts to make our business run as smooth as your skin after a LunchboxWax Brazilian. Yep, we just said that. Our business formula works, and we`re excited to share it through the LunchboxWax Franchise System.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.